A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

NCT06539507 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Netherton Syndrome

Interventions

DRUG: BCX17725
DRUG: Placebo

Sponsor

BioCryst Pharmaceuticals